本共识建立了成人动脉粥样硬化性心血管疾病（atherosclerotic cardiovascular disease，ASCVD）高危人群规范应用心脑宁胶囊以提升疗效的关键流程，概述了心脑宁胶囊的中医配伍理论、药学和药理研究特性，界定了心脑宁胶囊的精确适用人群、干预时机、病证疗效特点及优选应用方案，归纳了心脑宁胶囊的不良反应、使用禁忌、注意事项及非临床安全性等相关证据。本共识适合ASCVD相关专业领域的执业医师、执业中医医师和执业中西医结合医师使用。

This consensus established the atherosclerotic process in the adult cardiovascular disease (atherosclerotic cardiovascular diseases, ASCVD) high-risk groups use of Xinnaoning capsule in order to enhance the curative effect of key process, summarized the compatibility theory of traditional Chinese medicine, the pharmaceutical and pharmacological research characteristics of Xinnaoning Capsule, defined the accurate applicable people, the intervention time and curative effect of disease characteristics and optimization solutions of Xinnaoning Capsule, summarized the adverse reactions, taboo, matters needing attention, and non-clinical safety and other relevant evidence of Xinnaoning Capsule. This consensus is suitable for practicing physicians, practicing physicians of traditional Chinese medicine, and practicing physicians of integrated traditional Chinese and Western medicine in ASCVD related professional fields.

国家重点研发计划中医药现代化研究2018年度重点专项（2018YFC1707402）